Alfred Altomari - Agile Thrpe CEO and President and Director
| AGRXDelisted Stock | USD 2.94 0.08 2.65% |
CEO
Mr. Alfred Altomari serves as Chairman of the Board, President, Chief Executive Officer of Agile Therapeutics, Inc. From 2008 to September 2010, Mr. Altomari was also a consultant to Agile. From 2003 to 2008, Mr. Altomari held multiple senior management positions at Barrier Therapeutics, Inc., including Chief Commercial Officer, Chief Operating Officer, and Chief Executive Officer. In 2008, in his role as Chief Executive Officer and as a member of Barrier board of directors, Mr. Altomari completed the successful sale of Barrier to Stiefel Laboratories, which was subsequently acquired by GlaxoSmithKline plc. From 1982 to 2003, Mr. Altomari held numerous executive roles in general management, commercial operations, business development, product launch preparation, and finance with Johnson Johnson. Mr. Altomari also serves on the board of directors of Insmed Inc. and Recro Pharma, Inc. since 2016.
| Age | 65 |
| Tenure | 8 years |
| Phone | 609 683 1880 |
| Web | https://www.agiletherapeutics.com |
Agile Thrpe Management Efficiency
The company has return on total asset (ROA) of (0.9671) % which means that it has lost $0.9671 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (13.6404) %, meaning that it created substantial loss on money invested by shareholders. Agile Thrpe's management efficiency ratios could be used to measure how well Agile Thrpe manages its routine affairs as well as how well it operates its assets and liabilities.Agile Thrpe currently holds 2.21 M in liabilities with Debt to Equity (D/E) ratio of 3.95, implying the company greatly relies on financing operations through barrowing. Agile Thrpe has a current ratio of 0.63, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Agile Thrpe's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 11 records | CEO Age | ||
| Ilan MBA | Painreform | 55 | |
| David RPh | Evoke Pharma | 60 | |
| Chintu RPh | Amneal Pharmaceuticals, Class | 52 | |
| Stephen Gunstream | Alpha Teknova | 45 | |
| David Gonyer | Evoke Pharma | 60 | |
| Paul Josephs | Lifecore Biomedical | 59 | |
| Brendan OGrady | Assertio Therapeutics | N/A | |
| Keith Kendall | Aquestive Therapeutics | 66 | |
| Chirag Patel | Amneal Pharmaceuticals, Class | 57 | |
| James Hall | Lifecore Biomedical | 61 | |
| Chintu Patel | Amneal Pharmaceuticals, Class | 49 | |
Management Performance
| Return On Equity | -13.64 | |||
| Return On Asset | -0.97 |
Agile Thrpe Leadership Team
Elected by the shareholders, the Agile Thrpe's board of directors comprises two types of representatives: Agile Thrpe inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Agile. The board's role is to monitor Agile Thrpe's management team and ensure that shareholders' interests are well served. Agile Thrpe's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Agile Thrpe's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, Senior Officer | ||
| Jason Butch, VP Officer | ||
| Joseph DUrso, Controller | ||
| Robert ME, Senior Officer | ||
| Kathryn PharmD, Advisor | ||
| Alfred Altomari, CEO and President and Director | ||
| Matthew Riley, Head Communications | ||
| Amy Welsh, Senior Officer | ||
| Geoffrey Gilmore, Senior Officer | ||
| Scott Coiante, CFO and VP | ||
| MPH MD, Consultant |
Agile Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Agile Thrpe a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -13.64 | |||
| Return On Asset | -0.97 | |||
| Profit Margin | (0.70) % | |||
| Operating Margin | (0.60) % | |||
| Current Valuation | 633.86 K | |||
| Shares Outstanding | 2.96 M | |||
| Shares Owned By Insiders | 1.13 % | |||
| Shares Owned By Institutions | 10.13 % | |||
| Number Of Shares Shorted | 222.1 K | |||
| Price To Earning | (4.74) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Other Consideration for investing in Agile Stock
If you are still planning to invest in Agile Thrpe check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Agile Thrpe's history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |